Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin’s lymphoma: A retrospective analysis

Abstract

This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with the dose-dense ABVD regimen (ABVD-21) in terms of efficacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin’s lymphoma (HL) according to German Hodgkin Study Group criteria from March 1999 to February 2011 were analyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates after completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival (PFS) and overall survival (OS) rates (84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD). Subgroup analyses showed that ABVD-21 was significantly better than ABVD for patients with IPS≥3 in terms of PFS and OS rates. Grade 3 to 4 leukopenia (51.8% vs. 28.8%, P=0.001) and neutropenia (57.6% vs. 39.0%, P=0.009) were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor control and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS≥3, may benefit from dose-dense ABVD.

Keywords

dose-dense ABVD / standard ABVD / Hodgkin’s lymphoma / retrospective analysis

References

[1] FermeC, EghbaliH, MeerwaldtJH, et al.. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med, 2007, 357(19): 1916-1927

[2] EngertA, SchillerP, JostingA, et al.. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: Results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol, 2003, 21(19): 3601-3608

[3] FedericoM, LuminariS, IannittoE, et al.. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol, 2009, 27(5): 805-811

[4] VivianiS, ZinzaniPL, RambaldiA, et al.. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med, 2011, 365(3): 203-212

[5] CanellosGP, AndersonJR, PropertKJ, et al.. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 1992, 327(21): 1478-1484

[6] DugganDB, PetroniGR, JohnsonJL, et al.. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’sdisease: report of an intergroup trial. J Clin Oncol, 2003, 21(4): 607-614

[7] von TresckowB, PlütschowA, FuchsM, et al.. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol, 2012, 30(9): 907-913

[8] Russo F, Corazzelli G, Lastoria S, et al. Dose-dense(dd) ABVD and dose-dense/dose-intense(dd-di) ABVD in newly diagnosed patients (pts), intermediate- and advanced-stage with classical Hodgkin’s lymphoma (cHL): final results [abstract 715] (accessed at https://ash.confex.com/ash/2009/webprogram/Paper18244.html)

[9] ChesonBD, HorningSJ, CoiffierB, et al.. Report of an international workshop to standardized response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol, 1999, 17(4): 1244-1253

[10] EichHT, DiehV, GörgenH, et al.. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol, 2010, 28(11): 4199-4206

[11] HoskinPJ, LowryL, HorwichA, et al.. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymp-homa Group Study ISRCTN 64141244. J Clin Oncol, 2009, 27(32): 5390-5396

[12] GallaminiA, HutchingsM, RigacciL, et al.. Early interim 2-[18F]fluoro-2-deoxy-D-gluose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol, 2007, 25(24): 3746-3752